These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25365354)

  • 21. Challenges and Opportunities of Nanotechnological based Approach for the Treatment of Tuberculosis.
    Rath G; Pradhan D; Ghosh G; Goyal AK
    Curr Pharm Des; 2021; 27(17):2026-2040. PubMed ID: 33634753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nanotechnology and tuberculosis: An old disease with new treatment strategies.
    Macêdo DCDS; Cavalcanti IDL; Medeiros SMFRDS; Souza JB; Lira Nogueira MCB; Cavalcanti IMF
    Tuberculosis (Edinb); 2022 Jul; 135():102208. PubMed ID: 35567896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhaled Solid Lipid Microparticles to target alveolar macrophages for tuberculosis.
    Maretti E; Rossi T; Bondi M; Croce MA; Hanuskova M; Leo E; Sacchetti F; Iannuccelli V
    Int J Pharm; 2014 Feb; 462(1-2):74-82. PubMed ID: 24374224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotherapeutic potential of alginate-chitosan microspheres as anti-tubercular drug carriers.
    Pandey R; Khuller GK
    J Antimicrob Chemother; 2004 Apr; 53(4):635-40. PubMed ID: 14998985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Respirable nanocarriers as a promising strategy for antitubercular drug delivery.
    Mehanna MM; Mohyeldin SM; Elgindy NA
    J Control Release; 2014 Aug; 187():183-97. PubMed ID: 24878180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model.
    Pandey R; Khuller GK
    J Antimicrob Chemother; 2004 Jul; 54(1):266-8. PubMed ID: 15128731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pulmonary drug delivery systems for tuberculosis treatment.
    Pham DD; Fattal E; Tsapis N
    Int J Pharm; 2015 Jan; 478(2):517-29. PubMed ID: 25499020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tuberculosis drug discovery and emerging targets.
    Mdluli K; Kaneko T; Upton A
    Ann N Y Acad Sci; 2014 Sep; 1323():56-75. PubMed ID: 24920100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quinoline: a promising antitubercular target.
    Keri RS; Patil SA
    Biomed Pharmacother; 2014 Oct; 68(8):1161-75. PubMed ID: 25458785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clofazimine: current status and future prospects.
    Cholo MC; Steel HC; Fourie PB; Germishuizen WA; Anderson R
    J Antimicrob Chemother; 2012 Feb; 67(2):290-8. PubMed ID: 22020137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current nanotechnological strategies for effective delivery of bioactive drug molecules in the treatment of tuberculosis.
    Kaur M; Garg T; Rath G; Goyal AK
    Crit Rev Ther Drug Carrier Syst; 2014; 31(1):49-88. PubMed ID: 24579767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitubercular potential of plants: a brief account of some important molecules.
    Negi AS; Kumar JK; Luqman S; Saikia D; Khanuja SP
    Med Res Rev; 2010 Jul; 30(4):603-45. PubMed ID: 19626592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fighting tuberculosis: an old disease with new challenges.
    Tripathi RP; Tewari N; Dwivedi N; Tiwari VK
    Med Res Rev; 2005 Jan; 25(1):93-131. PubMed ID: 15389729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New Perspectives in Drug Delivery Systems for the Treatment of Tuberculosis.
    da Silva Leite JM; Patriota YBG; de La Roca MF; Soares-Sobrinho JL
    Curr Med Chem; 2022; 29(11):1936-1958. PubMed ID: 34212827
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Particulate and vesicular drug carriers in the management of tuberculosis.
    Rastogi R; Sultana Y; Ali A; Aqil M
    Curr Drug Deliv; 2006 Jan; 3(1):121-8. PubMed ID: 16472101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Anti-tuberculosis drugs].
    Doi N
    Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():367-74. PubMed ID: 17455647
    [No Abstract]   [Full Text] [Related]  

  • 37. Advances in nanotechnology for diagnosis and treatment of tuberculosis.
    Banyal S; Malik P; Tuli HS; Mukherjee TK
    Curr Opin Pulm Med; 2013 May; 19(3):289-97. PubMed ID: 23429097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review on various heterocyclic moieties and their antitubercular activity.
    Sharma S; Sharma PK; Kumar N; Dudhe R
    Biomed Pharmacother; 2011 Jul; 65(4):244-51. PubMed ID: 21715130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peptide deformylase--a promising therapeutic target for tuberculosis and antibacterial drug discovery.
    Sharma A; Khuller GK; Sharma S
    Expert Opin Ther Targets; 2009 Jul; 13(7):753-65. PubMed ID: 19530983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mycolic acids, a promising mycobacterial ligand for targeting of nanoencapsulated drugs in tuberculosis.
    Lemmer Y; Kalombo L; Pietersen RD; Jones AT; Semete-Makokotlela B; Van Wyngaardt S; Ramalapa B; Stoltz AC; Baker B; Verschoor JA; Swai HS; de Chastellier C
    J Control Release; 2015 Aug; 211():94-104. PubMed ID: 26055640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.